Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | BDKRB1 | P46663 | 12/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16198683 | 1.00 | MME (0.53) | MMEACEBDKRB1 | |
| SCHEMBL9934810 | 0.90 | MME (0.63) | MMEACEBDKRB1 | |
| SCHEMBL9934806 | 0.90 | MME (0.63) | MMEACEBDKRB1 | |
| SCHEMBL19714804 | 0.89 | MME (0.56) | MMEACEBDKRB1 | |
| SCHEMBL16198684 | 0.89 | MME (0.56) | MMEACEBDKRB1 | |
| SCHEMBL9936054 | 0.89 | MME (0.64) | MMEACEBDKRB1 | |
| SCHEMBL9936060 | 0.89 | MME (0.64) | MMEACEBDKRB1 | |
| SCHEMBL9935366 | 0.88 | MME (0.65) | MMEACEBDKRB1 | |
| SCHEMBL9935362 | 0.88 | MME (0.65) | MMEACEBDKRB1 | |
| SCHEMBL19714802 | 0.88 | MME (0.55) | MMEACEBDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981999-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-29 | — | — | US | claimed |
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885BDKRB1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.